Autophagy in blood cancers: biological role and therapeutic implications

Nencioni, A., Cea, M., Montecucco, F., Longo, V.D., Patrone, F., Carella, A.M., Holyoake, T.L. and Helgason, G.V. (2013) Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 98(9), pp. 1335-1343. (doi: 10.3324/haematol.2012.079061)

[img]
Preview
Text
89660.pdf - Published Version

391kB

Abstract

Autophagy is a cell recycling process the molecular apparatus of which has been identified over the past decade. Autophagy allows cells to survive starvation and inhospitable conditions and plays a key role in numerous physiological functions, including hematopoiesis and immune responses. In hematologic malignancies, autophagy can either act as a chemo-resistance mechanism or have tumor suppressive functions, depending on the context. In addition, autophagy is involved in other important aspects of blood cancers as it promotes immune competence and anti-cancer immunity, and may even help enhance patient tolerance to standard treatments. Approaches exploiting autophagy, either to activate or inhibit it, could find broad application in hematologic malignancies and contribute to improved clinical outcomes. These aspects are discussed here together with a brief introduction to the molecular machinery of autophagy and to its role in blood cell physiology.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Helgason, Professor Vignir
Authors: Nencioni, A., Cea, M., Montecucco, F., Longo, V.D., Patrone, F., Carella, A.M., Holyoake, T.L., and Helgason, G.V.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Haematologica
Publisher:Fondazione Ferrata Storti
ISSN:0390-6078
ISSN (Online):1592-8721
Copyright Holders:Copyright © 2013 Ferrata Storti Foundation
First Published:First published in Haematologica 98(9):1335-1343
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
503111A randomised Phase II trial of Imatinib (IM) versus hydroxychloroquine (HCQ) with IM for patients with chronic myeloid leukaemia (CML) in cytogenic response (CyR)- CHOICESTessa HolyoakeMedical Research Council (MRC)G0900882RI CANCER SCIENCES
516251Targeting autophagy as a tool to potentiate Imatinib-induced cell death in CML cellsTessa HolyoakeKay Kendal Leukaemia Fund (KAY-KENDAL)KKL404RI CANCER SCIENCES